AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to ...

EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody ...

EsoBiotec’s platform has the potential to transform cell therapy by empowering the immune system to attack cancers ...

FTSE 100 Live Monday Qinetiq warning hits sharesAstraZeneca unveils £1bn dealPhoenix rallies on new guidance ...